Drug Database
Back to search

Japan· JP-2290402G1020

ベンラリズマブ（遺伝子組換え）

A benralizumab product containing ベンラリズマブ（遺伝子組換え）, registered in Japan by アストラゼネカ, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.

On Japan’s NHI price listATC R03DX10

Checked against MHLW / PMDA (Japan) on

Informational only — not a medical device.

SOURCE REGISTER · JPMHLW / PMDA (Japan)normalisedベンラリズマブ（遺伝子組換え）ATCR03DX10REGISTER NO.JP-2290402G1020PACKS LISTED0CHECKEDSeptember 25, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about ベンラリズマブ（遺伝子組換え）Answers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Benralizumab is registered in 16 of 19 countries.

Countries holding a registration under ATC R03DX10 (benralizumab), each read from that country’s own register.

  • This record: Japan, from MHLW / PMDA (Japan)
  • 10 of them publish a price we can compare per daily dose
Search benralizumab products by name

Benralizumab · ATC R03DX10

16 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

MHLW / PMDA (Japan)
Active substance
ベンラリズマブ（遺伝子組換え）
Manufacturer
アストラゼネカ
Country
Japan (JP)
ATC code
R03DX10
ATC class
Benralizumab
Defined daily dose
0.54 mg, P
Reimbursed
Yes
Source register
MHLW / PMDA (Japan)
Last checked
September 25, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Benralizumab in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All benralizumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Fasenra
  • Liechtenstein · Fasenra
  • Norway · Fasenra

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/e1252a6e-bf7d-456d-a753-405fd42a9c79
GET /v1/drugs/e1252a6e-bf7d-456d-a753-405fd42a9c79?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "spec": "３０ｍｇ１ｍＬ１筒",
  "marks": null,
  "source": "mhlw",
  "remarks": null,
  "yj_code": "2290402G1020",
  "category": "注射薬",
  "price_yen": 335309,
  "generic_name": "ベンラリズマブ（遺伝子組換え）",
  "product_name_jp": null,
  "therapeutic_class": "2290",
  "transitional_expiry": null
}
API referenceMCP serverPlans

See everything about benralizumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console